Cargando…

A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling

Glioblastoma (GBM) is one of the most aggressive brain malignancies with high incidences of developing treatment resistance, resulting in poor prognoses. Glioma stem cell (GSC)-derived exosomes are important players that contribute to GBM tumorigenesis and aggressive properties. Herein, we investiga...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Alexander T. H., Huang, Hsu-Shan, Wen, Ya-Ting, Lawal, Bashir, Mokgautsi, Ntlotlang, Huynh, Thanh-Tuan, Hsiao, Michael, Wei, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471927/ https://www.ncbi.nlm.nih.gov/pubmed/34572040 http://dx.doi.org/10.3390/cells10092391

Ejemplares similares

Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines
por: Lawal, Bashir, et al.
Publicado: (2021)

Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent
por: Chinyama, Harold A., et al.
Publicado: (2023)

mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2′,4′-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications
por: Lawal, Bashir, et al.
Publicado: (2021)

An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential GSK3β/β-Catenin/STAT3/CD44 Suppressor with Anti-Glioblastoma Properties
por: Mokgautsi, Ntlotlang, et al.
Publicado: (2021)

Network Pharmacological Analysis through a Bioinformatics Approach of Novel NSC765600 and NSC765691 Compounds as Potential Inhibitors of CCND1/CDK4/PLK1/CD44 in Cancer Types
por: Mokgautsi, Ntlotlang, et al.
Publicado: (2021)

In-Silico Evaluation of Genetic Alterations in Ovarian Carcinoma and Therapeutic Efficacy of NSC777201, as a Novel Multi-Target Agent for TTK, NEK2, and CDK1
por: Khedkar, Harshita Nivrutti, et al.
Publicado: (2021)

HNC0014, a Multi-Targeted Small-Molecule, Inhibits Head and Neck Squamous Cell Carcinoma by Suppressing c-Met/STAT3/CD44/PD-L1 Oncoimmune Signature and Eliciting Antitumor Immune Responses
por: Lee, Jih-Chin, et al.
Publicado: (2020)

Anticancer Activities of 9-chloro-6-(piperazin-1-yl)-11H-indeno[1,2-c] quinolin-11-one (SJ10) in Glioblastoma Multiforme (GBM) Chemoradioresistant Cell Cycle-Related Oncogenic Signatures
por: Mokgautsi, Ntlotlang, et al.
Publicado: (2022)

Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence
por: Mecca, Carmen, et al.
Publicado: (2018)

Targeting the Axl and mTOR Pathway Synergizes Immunotherapy and Chemotherapy to Butylidenephthalide in a Recurrent GBM
por: Liu, Ching-Ann, et al.
Publicado: (2022)

Preclinical Identification of Sulfasalazine’s Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling
por: Leung, Wai-Hung, et al.
Publicado: (2022)

In Vitro and In Silico Biological Studies of 4-Phenyl-2-quinolone (4-PQ) Derivatives as Anticancer Agents
por: Chen, Yi-Fong, et al.
Publicado: (2023)

Ras and Wnt Interaction Contribute in Prostate Cancer Bone Metastasis
por: Lin, Shian-Ren, et al.
Publicado: (2020)

Preclinical Evaluation of a Novel Small Molecule LCC-21 to Suppress Colorectal Cancer Malignancy by Inhibiting Angiogenic and Metastatic Signatures
por: Mokgautsi, Ntlotlang, et al.
Publicado: (2023)

Re-thinking the preclinical development of GBM therapeutics
por: Cosset, Érika, et al.
Publicado: (2018)

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
por: Garrido-Laguna, I, et al.
Publicado: (2010)

STAT3 and mTOR: co-operating to drive HIF and angiogenesis
por: Dodd, Kayleigh M., et al.
Publicado: (2015)

CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation
por: Shuda, Masahiro, et al.
Publicado: (2015)

FAM72, Glioblastoma Multiforme (GBM) and Beyond
por: Ho, Nguyen Thi Thanh, et al.
Publicado: (2021)

Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma
por: Balsas, P., et al.
Publicado: (2017)

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways
por: Hosford, Sarah R, et al.
Publicado: (2014)

Bazedoxifene inhibits sustained STAT3 activation and increases survival in GBM
por: Wightman, Samantha M., et al.
Publicado: (2021)

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
por: O’Brien, Neil A., et al.
Publicado: (2020)

CDK7 inhibition is a novel therapeutic strategy against GBM both in vitro and in vivo
por: Meng, Wei, et al.
Publicado: (2018)

Comprehensive Omics Analysis of a Novel Small-Molecule Inhibitor of Chemoresistant Oncogenic Signatures in Colorectal Cancer Cell with Antitumor Effects
por: Huang, Tse-Hung, et al.
Publicado: (2021)

In Silico Evaluation of HN-N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non-Small Cell Lung Cancer
por: Chen, Lung-Ching, et al.
Publicado: (2023)

EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Status Report of the HARP experiment, 2002-019
por: Dydak, Friedrich, et al.
Publicado: (2002)

O019. Headache as an emergency in children and adolescents
por: Papetti, Laura, et al.
Publicado: (2015)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
por: Rodriguez, María Jimena, et al.
Publicado: (2023)

AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
por: Abu-Khalaf, Maysa M., et al.
Publicado: (2023)

HGG-16. EXOSOME-MEDIATED INTER-CLONAL INTERACTIONS IN PEDIATRIC GBM AND DIPG
por: Pericoli, Giulia, et al.
Publicado: (2020)

The Exosome-Mediated PI3K/Akt/mTOR Signaling Pathway in Neurological Diseases
por: Iranpanah, Amin, et al.
Publicado: (2023)

Mitochondrial DNA Alterations in Glioblastoma (GBM)
por: Leão Barros, Mariceli Baia, et al.
Publicado: (2021)

Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis
por: Mammana, Santa, et al.
Publicado: (2018)

Preclinical Efficacy and Involvement of AKT, mTOR, and ERK Kinases in the Mechanism of Sulforaphane against Endometrial Cancer
por: Rai, Rajani, et al.
Publicado: (2020)

mTOR inhibition by TAK‐228 is effective against growth, survival and angiogenesis in preclinical retinoblastoma models
por: Tang, Lanlan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7kcm5eeu8isvrdp8q3vv164j5r